HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity
28 oct. 2024 10h00 HE
|
HOPO Therapeutics, Inc.
HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity
Crossject annonce des progrès majeurs dans la fabrication de son traitement d’urgence ZEPIZURE®, pour la prise en charge des crises d’épilepsie, à l’approche du dépôt d’une demande d’autorisation d’utilisation d’urgence aux États-Unis.
22 oct. 2024 01h30 HE
|
CROSSJECT
Le lot de produits annoncé en juillet a permis de recueillir davantage de données de stabilité, qui au premier trimestre 2025 soutiendront directement la stabilité requise de six mois.Crossject...
Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization
22 oct. 2024 01h30 HE
|
CROSSJECT
Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file...
BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
22 oct. 2024 00h30 HE
|
BioAegis Therapeutics
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
17 oct. 2024 08h07 HE
|
BioAegis Therapeutics
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC
12 sept. 2024 16h56 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its...
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
12 sept. 2024 08h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract modification executing an option period by the Biomedical...
Crossject franchit une nouvelle étape clé dans la fabrication de ZEPIZURE®
18 juil. 2024 01h30 HE
|
CROSSJECT
Fabrication réussie d’un autre Lot Règlementaire de ZEPIZURE® sur le nouveau site de fabricationUne étape importante qui complète les résultats satisfaisants obtenus avec les lots précédents dans le...
Crossject achieves key ZEPIZURE® manufacturing milestone
18 juil. 2024 01h30 HE
|
CROSSJECT
Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is...
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
24 juin 2024 08h02 HE
|
InflaRx N.V.
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced...